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Expansion of polyglutamine tracts in nine different genes causes selective neuronal degeneration through
unknown mechanisms. Expansion of polyglutamine in the androgen receptor is responsible for spinal and
bulbar muscular atrophy (SBMA), a neuromuscular disorder characterized by the loss of lower motor
neurons in the brainstem and spinal cord. A unique feature of SBMA in the family of polyglutamine dis-
eases is sex speciﬁcity. SBMA fully manifests only in males. SBMA is a disease triggered by the binding of
polyglutamine androgen receptor to its natural ligand testosterone. Recent evidence has emerged show-
ing that the expanded polyglutamine tract itself is not the only determinant of disease pathogenesis.
There is evidence that both the native structure and function of the disease protein strongly inﬂuence
the pathogenicity of mutant protein. Here, we review recent progress in the understanding of disease
pathogenesis and advancements towards development of potential therapeutic strategies for SBMA.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Spinal and bulbar muscular atrophy (SBMA), also known as
Kennedy’s disease, was ﬁrst described in the nineteenth century
by Hiroshi Kawahara and again nearly a century later by William
Kennedy [51,52]. The gene coding for androgen receptor (AR)
was cloned in 1988 by three independent groups [10,60,109] and
linked to SBMA three years later [55]. The causative mutation in
SBMA is the expansion of a CAG trinucleotide repeat, which en-
codes a polyglutamine (polyQ) tract, in the AR gene. The polyQ
tract is polymorphic in length. In normal individuals, the polyQ
stretch ranges between 9 and 36 residues, and expansion over 38
and up to 62 residues is pathogenic. SBMA is one of nine neurode-
generative disorders caused by expansion of polyQ tracts. These
disorders are known as polyQ diseases and include Huntington’s
disease, dentatorubral–pallidoluysian atrophy, and six types of
spinocerebellar ataxia (SCA), known as SCA1, SCA2, SCA3, SCA6,
SCA7, and SCA17 [77,84]. The causative genes are huntingtin
[61], atrophin-1 [54,70], ataxin-1 [76], ataxin-2 [39], ataxin-3
[50], CACNA1A [119], ataxin-7 [17], and the TATA-binding protein
(TBP) [71], respectively. PolyQ diseases share several features. All
of these diseases are neurodegenerative disorders with typically
late onset, and all are inherited in an autosomal dominant fashion
except SBMA, which is X-linked. There is a positive correlation
between CAG repeat length and disease severity, and a negativeY-NC-ND license. 
.
d Brain Technologies, Istitutocorrelation between repeat length and the age of disease onset.
Similar to other repeat expansion disorders, polyQ diseases show
genetic anticipation, a phenomenon in which one generation
shows a more severe phenotype and an earlier onset of disease
compared with the previous generation, due to the fact that the re-
peat tends to expand when it is passed down from one generation
to the next. Despite several common features shared by polyQ dis-
eases, expansion of polyQ tracts in the different proteins causes
degeneration only in speciﬁc neuronal subpopulations in each dis-
ease. This selective neuronal vulnerability results in clinically dis-
tinct disease phenotypes. Recently, evidence has emerged
suggesting that there is a strong relationship between the structure
and function of polyQ proteins with toxicity [11,25,59,80]. A major
limitation in the study of polyQ disease pathogenesis comes from
the lack of information related to protein structure and, more
importantly, protein function. SBMA represents an exception in
the polyQ ﬁeld, as a large body of information about AR protein
structure and function is available to date. Pathological features
of polyQ diseases are discussed elsewhere [6,77,94,101]. This re-
view will focus on SBMA.
2. Clinical features of SBMA
SBMA is a neuromuscular disease. The prevalence of the disease
is estimated to be 1–2/100,000 in the male population of Western
European descent, although this is likely to be an underestimation,
as patients can be misdiagnosed or undiagnosed [26,82]. SBMA
typically has a late onset around the third to ﬁfth decade of life
and a relatively slow progression, although a family case with juve-
nile onset and fast progression has been reported [23]. SBMA is
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in the brainstem and spinal cord, together with progressive weak-
ness, atrophy and fasciculation of proximal limb and bulbar mus-
cles. Distal muscle weakness and atrophy are observed in the
arms more than the legs. Cramps, hand tremor and fatigue often
precede muscle weakness, sometimes by several years. As motor
dysfunction progresses, patients may require the use of canes
and wheelchairs. Patients show facial fasciculations with contrac-
tion of muscles around the mouth and chin, fasciculation of the
tongue, and in some cases dysarthria and dysphagia. SBMA pa-
tients also show signs of mild subclinical sensory impairment.
Neurologic examination can reveal diminished or absent deep ten-
don reﬂex. Other symptoms include endocrine abnormalities, such
as diabetes mellitus, as well as signs of mild androgen insensitivity,
including gynecomastia, reduced fertility and testicular atrophy.
Androgen levels in the serum of SBMA patients are normal, or in
some cases elevated. A unique feature of SBMA among polyQ dis-
eases is sex speciﬁcity, as SBMA fully manifests only in males. Be-
cause the gene coding for AR is on the X chromosome, the disease
was initially thought to be recessive. However, females homozy-
gous for the mutation were described to have only subclinical dis-
ease manifestations, which could not be explained with a canonical
recessive pattern of inheritance for an X-linked mutation [92]. This
conundrum was elucidated with the development of animal mod-
els of SBMA. The sex speciﬁcity of SBMA is indeed well recapitu-
lated in both vertebrate and invertebrate animal models of the
disease. For instance, in transgenic mice expressing mutant AR,
the disease fully manifests only in males [12,45,118]. Importantly,
manipulation of androgen levels in animals dictates disease mani-
festations: treatment of transgenic female mice with testosterone
induces disease manifestations, while castration of transgenic male
mice prevents degeneration. Expression of mutant AR in Drosophila
melanogaster causes degeneration only if the ﬂies are reared in a
hormone-containing food [102]. This evidence provides proof of
principle that SBMA is a disease triggered by the binding of
polyQ-AR to its natural ligands, testosterone and its more potent
derivative dihydrotestosterone (DHT).
3. Structure–function relationship of AR
The AR gene maps on the long arm of the X chromosome
(Xq11–12) and is composed of eight exons (Fig. 1). AR is a protein
of approximately 919 amino acids with a molecular weight of
about 110 kDa. AR belongs to the family of steroid hormone recep-
tors, which includes the estrogen receptor, glucocorticoid receptor,
progesterone receptor and mineralocorticoid receptor. Similar toFig. 1. Scheme of AR gene and protein. The AR gene is composed of eight exons. The ﬁrst e
a poly-proline tract (polyP) and a poly-glycine tract (polyG). The ﬁrst polyQ tract (red) is e
by two zinc ﬁngers, and the hinge region, which contains the PEST sequence and the nucthe other members of the family, AR has a very well-deﬁned do-
main structure. AR is composed of an amino-terminal domain, a
DNA-binding domain, and a ligand-binding domain, which is
linked to the DNA-binding domain by a hinge region (Figs. 1 and 2).
3.1. Amino-terminal domain
The amino-terminal domain of AR is encoded by exon 1 (amino-
acids 1–555, NM_000044). In the family of steroid receptors, this
domain is the less well-conserved portion of the protein compared
to the other protein domains. The amino-terminal domain contains
two highly polymorphic repeats, the polyQ and the polyglycine
tracts. Although the functional role of these repeats remains to
be elucidated, there is a strikingly tight correlation between AR
function and polymorphic AR variants. For example, there is an in-
verse correlation between polyQ repeat length and AR transactiva-
tion: the longer the repeat, the lower the ligand-dependent AR
transactivation [31,110,112]. In addition, the effect of polyQ tract
polymorphisms on AR function correlates well with androgen-re-
lated disorders. Indeed, epidemiologic studies show that individu-
als carrying a polyQ tract shorter than 20 glutamine residues are at
increased risk for prostate cancer compared to individuals with re-
peats longer than 26 residues [28,38,98]. Conversely, AR with a
polyQ tract longer than 28 residues has been associated with male
infertility [110]. Importantly, AR transactivation decreases with
pathologic lengths of the polyQ tract, which may account for the
signs of androgen insensitivity observed in SBMA patients [65].
Human AR has two other relatively short polyQ tracts in the ami-
no-terminal domain, one composed of ﬁve (amino-acids 86–91)
and the other of six (amino-acids 195–199) glutamine residues.
Interestingly, these polyQ tracts also negatively regulate AR trans-
activation [31].
The polyglycine tract is encoded by the GGN trinucleotide re-
peat (amino-acids 451–473). While the effect of the length of the
polyQ tract on AR function is well established, the effect of the
polyglycine tract is less clear and may depend on cell context
and on cis-elements on the promoter of target genes
[20,27,36,115]. The impact of the polyglycine tract on the SBMA
phenotype is not known.
In addition to the polyQ and the polyglycine stretches, the ami-
no-terminal domain of AR contains a polyproline tract, which is
composed of eight residues (amino-acids 374–381). The functional
role of this amino acid sequence in AR is not known, although there
is evidence that polyproline-rich sequences reduce toxicity in Hun-
tington’s disease. Huntingtin has two polyproline tracts separated
by a proline-rich sequence. Presence of this amino acid tract on thexon encodes the amino-terminal domain, which contains three polyQ tracts (polyQ),
xpanded in SBMA. Exons 2 and 3 encode the DNA-binding domain, which is formed
lear localization signal (NLS). Exons 4 through 8 encode the ligand-binding domain.
Fig. 2. AR sequence (NM_000044). The AR sequence has been subdivided in the amino-terminal domain, DNA-binding domain and hinge region, and ligand-binding domain.
Amino-terminal domain: Amino-acids 1–555. The pathogenic polyQ tract is highlighted in red, while the other polyQ tracts, the poly-proline tract and the poly-glycine tract
are in yellow. The FXXLF (FQNLF) and WXXLF (WHTLF) motifs are in bold-cyan. DNA-binding domain and hinge region: Amino-acids 556–670. The zinc ﬁngers are underlined,
and the nuclear localization signal is double-underlined. The calreticulin-binding site (KVFFKR), the acetylation consensus sequence (KLKK), and the PEST sequence (SPTE) are
in bold-cyan. Ligand-binding domain: Amino-acids 671–920.
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and toxicity both in vitro and in vivo [7,16,19,22]. Whether the
polyproline tract of AR inﬂuences the toxic properties of mutant
protein remains to be established.
In the amino-terminal domain, AR has two domains critical for
AR function: activation function 1 (AF-1) and activation function 5
(AF-5). AF-1 spans amino-acids 51–211 and is critical for andro-
gen-dependent regulation of gene transcription. This domain is li-
gand-dependent, and it is masked by the interaction of AR with
heat shock proteins in the inactive state. AF-5 spans amino-acids
370–494. These two domains are required for interaction with
co-regulators of transcription. The role of these domains, if any,
in SBMA pathogenesis is unknown.3.2. DNA-binding domain and hinge region
The DNA-binding domain and the hinge region of AR are en-
coded by exons 2 and 3 (amino-acids 556–670). The DNA-binding
domain of AR is highly conserved and is composed of two zinc ﬁn-
gers. The ﬁrst zinc ﬁnger contacts the major groove of DNA and is
required for speciﬁcity in DNA binding, while the other zinc ﬁnger
is required for stabilization of the DNA–protein interaction. The
DNA-binding domain and hinge region contain a nuclear localiza-
tion signal (amino-acids 617–634), which drives AR to the nucleus
in response to ligand binding. The nuclear localization signal of AR
is bipartite, as it is formed by two clusters of conserved basic res-
idues separated by 10 amino acids [96]. Nuclear import of AR is
mediated by the importin-a and importin-b systems, and binding
of AR to importin-amainly involves the second cluster of basic res-
idues in the hinge region (residues 629–634) [15]. Additional nu-
clear localization signals in the amino-terminal domain as well
as in the ligand-binding domain have been identiﬁed [43].
The hinge region (628–669) of AR contains a PEST sequence (AR
sequence 651SPTE654, where P is proline, E glutamic acid, S serine,
and T threonine), which targets proteins for degradation through
the proteasome [88]. Deletion of this sequence results in increasedaccumulation of AR, which is further enhanced by proteasome
inhibition, suggesting a role for this sequence in proteasome-med-
iated AR degradation [103].
The nuclear localization signal contains the acetylation motif
KXKK (AR sequence 631KLKK634, where K is lysine and L leucine).
Deletion or mutation of this sequence decreases nuclear transloca-
tion but enhances AR transactivation [29,79,104,106]. The DNA
binding domain and hinge region of AR contain the calreticulin-
binding motif KXFFKR (AR sequence 581KVFFKR586, where V is
valine, F phenylalanine, and R arginine) [18]. Interestingly, calreti-
culin has been shown to interact with AR in the nucleus and to
inhibit DNA binding and transactivation, thereby inhibiting neuro-
nal differentiation in vitro. It would be interesting to determine
whether this motif plays a role in SBMA pathogenesis.3.3. Ligand-binding domain
The ligand-binding domain of AR is encoded by exons 4 through
8 (amino-acids 671–920). This domain is relatively well conserved
in the family of steroid receptors and is formed by helix-1 to -12
and four b-strands assembled into a three-layer a-helical structure
[63]. Upon ligand binding, this domain undergoes a conformational
change that leads to the assembly of activation function 2 (AF-2).
AF-2 is composed of helix-3, -4, -5 and -12 and consists of a hydro-
phobic surface ﬂanked by two charged residues, K720 and E897.
Helix-12 is particularly important, as it is repositioned differently
depending on the nature of the ligand [113]. In the agonist-bound
state, helix-12 works as a lid to close the pocket, while when in the
antagonist-bound state, helix-12 leaves the pocket open. In most
steroid receptors, AF-2 plays a major role in receptor transactiva-
tion by serving as the interaction surface for transcriptional co-reg-
ulators that contain an LXXLL motif. However, the AF-2 of AR has
relatively weak activity per se, and preferentially binds to the
FXXLF motif (AR sequence 23FQNLF27) and theWXXLF motif (AR se-
quence 435WHTLF439) in the amino-terminal domain of AR [34].
This results in an interaction between the amino-terminal domain
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tion [56,57]. The N/C interaction can be intra-molecular or inter-
molecular, the ﬁrst likely occurring in the cytosol, while the other
taking place upon transport to the nucleus [91].
4. Molecular mechanisms of disease pathogenesis
Does polyQ expansion in AR cause disease through a loss of
function or a gain of function mechanism? The endocrine abnor-
malities observed in SBMA patients indicate that polyQ expansion
leads to a partial loss of AR function. Genetic evidence in mouse
models supports the idea that the loss of AR function caused by
polyQ expansion contributes to disease pathogenesis [107]. How-
ever, a pure loss of function mechanism is difﬁcult to reconcile
with the observation that mutations that completely abolish AR
function result in androgen insensitivity syndrome with no signs
of neurodegeneration. Rather, expansion of polyQ is thought to
confer a toxic gain of function to the mutant protein. The last dec-
ade has brought an extensive advancement towards the molecular
characterization of the details through which polyQ expansion al-
ters AR biology and function (Fig. 3). These ﬁndings are summa-
rized in this section.
4.1. Interaction with heat shock proteins
In the cytosol, AR is bound to heat shock proteins (Hsps),
including Hsp90, Hsp70, and Hsp40. AR exists in two different
complexes, one containing p23, and the other not. The p23-con-
taining complex stabilizes the Hsp90-client proteins. The other
complex promotes protein folding and solubilization and targets
proteins for proteasomal degradation. Overexpression of Hsps in
animal models of SBMA and other polyQ diseases has been shown
to decrease the toxicity of polyQ proteins by promoting proteinFig. 3. Towards therapy for SBMA. In the inactive state, AR localizes to the cytosol in ass
AR from Hsps and translocation to nucleus. Also, ligand binding induces a conformationa
interactions. Ligand induces polyQ-AR aggregation and inclusion formation. Nuclear trans
and regulation of expression of androgen-responsive genes. Pharmacologic interventio
compounds have been successfully used to increase the association of polyQ-AR with Hsp
serum and to inhibit the conversion of testosterone to its more potent derivative dihydr
polyQ-AR to reduce N/C interactions. Modulation of HspB8 expression reduces aggregat
effects on toxicity. Activation of autophagy by rapamycin prevents neurodegenration. ASC
butyrate helps to reverse transcription dysregulation. Growth factor and neurotroph
mitochondrial dysfunction.degradation and reducing protein aggregation [1,3,37,40]. The ef-
fect of manipulation of Hsp levels on polyQ toxicity highlights this
as a potential therapeutic avenue for SBMA.
4.2. Nuclear translocation: keep it out!
Ligand binding results in the dissociation of the receptor from
Hsps and translocation to the nucleus. To determine whether li-
gand converts polyQ-AR into a toxic species because it brings the
disease protein to the nucleus, several AR variants were generated
with either mutations of the acetylation site KXKK, addition of a
nuclear export signal, or deletion of the nuclear localization signal.
These mutations block or reduce nuclear translocation without
altering ligand binding. These AR variants suppress polyQ-AR tox-
icity, indicating that nuclear translocation is a prerequisite for tox-
icity [68,72,102]. Similar to SBMA, nuclear localization of other
polyQ proteins has been shown to be critical for neurodegenera-
tion [8,53,90]. To what extent is nuclear translocation important
for toxicity? PolyQ-AR fused to a nuclear localization signal local-
izes to the nucleus in the absence of ligand, but fails to trigger neu-
rodegeneration, indicating that nuclear translocation is necessary,
but not sufﬁcient for toxicity [68,72]. This observation implies that
events beyond ligand-induced nuclear translocation are central to
disease pathogenesis.
4.3. N/C interaction
Ligand binding results in a conformational change that leads to
the AR N/C interaction. The ligand-induced N/C interaction has
been shown to be critical for toxicity. Indeed, disruption of the
N/C interaction through manipulation of the FXXLF motif reduces
mutant protein aggregation and toxicity in cell models of SBMA
[75]. The N/C interaction results in protein stabilization [32], andociation with heat shock proteins (Hsps). Ligand binding leads to the dissociation of
l change, which leads to intra- or inter-molecular AR amino/carboxy-terminal (N/C)
location is followed by DNA binding, which in turn leads to co-regulator recruitment
n has been developed to target many of these steps. 17-AAG and its derivative
s. Leuprorelin and dutasteride have been used to decrease testosterone levels in the
otestosterone, respectively. Flutamide and the SARMs RTI-016 and RTI-051b target
ion, while B2 increases the deposition of mutant AR into inclusions, with beneﬁcial
-J9 targets co-regulator recruitment, while the histone deacetylase inhibitor sodium
in modulation attenuates other aspects of disease, such as muscle atrophy and
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interaction attenuates toxicity. Protein stabilization is likely to play
a role in disease pathogenesis, as modiﬁcations that hamper the
effect of ligand on protein stabilization, i.e. phosphorylation of
polyQ-AR by Akt, are associated with reduced toxicity in vitro
and in vivo [78,80].4.4. PolyQ aggregation and inclusion formation
Expanded polyQ tracts form anti-parallel beta-strands held to-
gether by hydrogen bonds formed between the main chain of
one strand and the side chain of the adjacent strand [85]. This leads
the polyQ protein to acquire a non-native beta-sheet conformation,
which results in the accumulation of misfolded protein into micro-
aggregates/oligomers and inclusions. Micro-aggregates are rela-
tively small species that can be detected by biochemistry as the
material that accumulates in either the stacking portion of
SDS–polyacrylamide gels in Western blotting or in the acetate
membrane of a ﬁlter retardation assay [79,80]. Inclusions are larger
species detectable by immunocytochemistry and immunohisto-
chemistry. The biological role of protein inclusions is not entirely
clear. There is evidence that inclusions are protective species [4],
and that diffuse nuclear mutant AR may be the toxic species [2].4.5. DNA binding
AR binds to DNA following ligand-induced nuclear translocation
and a signiﬁcant conformational change. Importantly, a mutation
that abolishes the binding of polyQ-AR to DNA without interfering
with ligand binding, i.e. substitution of alanine 574 with aspartate,
suppresses toxicity in a Drosophila model of SBMA, indicating that
DNA binding is a prerequisite for toxicity in this system [72]. This
ﬁnding also indicates that the native function of the disease pro-
tein and events occurring in response to DNA binding are impor-
tant for toxicity.4.6. Co-regulator recruitment
The binding of AR to DNA is followed by the recruitment of tran-
scriptional co-regulators, both co-activators and co-repressors of
transcription [111]. The interaction between AR and transcription
co-regulators is ligand-dependent. Substitution of K720 with
alanine (K720A) disrupts the LXXLL-mediated interactions with
AF-2 and partially alters the FXXLF-mediated interactions, while
substitution of E897 with lysine (E897K) disrupts both the LXXLL-
and the FXXLF-mediated interactions [21,33]. Importantly, K720A
and E897K substitutions in polyQ-AR have been shown to prevent
toxicity in ﬂies, indicating that binding of mutant AR to co-
regulators is a critical event for pathogenesis in vivo [72]. These
ﬁndings imply that the mechanism underlying polyQ disease
pathogenesis involves modiﬁcation of the normal function of the
disease protein, and this is supported also from studies on other
polyQ diseases [25,59].4.7. Regulation of gene transcription
AR is a transcription factor that speciﬁcally regulates the
expression of hormone-responsive genes. Transcription dysregula-
tion is central to polyQ disease pathogenesis [35], and polyQ
expansion in AR leads to transcription dysregulation in cell and
ﬂy models of SBMA [58,72]. Although the mechanism through
which polyQ expansion affects AR function is not known, chronic
transcription dysregulation in motor neurons is likely to lead to
neuronal dysfunction and death.4.8. Axonal transport
Transcription dysregulation in SBMA mice results in altered
expression of several genes, including dynactin 1, which is a cen-
tral regulator of axonal transport [47]. Fast axonal transport has
been shown to be altered in SBMA cells in a process that depends
on c-Jun N-terminal kinase activation [69]. Because neurons rely
on fast axonal transport for neurotrophic support, the effect of pol-
yQ expansion on this process is likely to play an essential role in
disease pathogenesis. However, axonal transport defects were
not detected in an animal model of SBMA [62].
4.9. Mitochondrial dysfunction
Another gene whose transcription is dysregulated in SBMA cells
is peroxisome proliferator-activated receptor gamma coactivator-1
(PGC-1) [87]. PGC-1 is a transcription factor essential for mito-
chondrial biogenesis and function. Mutant AR has been shown to
alter mitochondrial function, as amino-terminal polyQ-AR frag-
ments induce Bax-dependent cytochrome c release and apoptosis
in primary cortical neurons [117]. Full-length polyQ-AR causes
mitochondrial membrane depolarization and accumulation of
reactive oxygen species, an effect that can be attenuated by treat-
ment of the cells with the antioxidants co-enzyme Q and idebe-
none [87]. Recently, abnormalities in the mitochondria of
leukocytes derived from SBMA patients and carriers were reported
[99]. These ﬁndings suggest a role for mitochondrial dysfunction in
SBMA pathogenesis.
Ligand binding induces several other post-translational modiﬁ-
cations, including phosphorylation and others. The impact of these
modiﬁcations on protein function and polyQ toxicity is discussed
elsewhere [83].5. Clinical perspectives for SBMA
Although there is currently no treatment available to arrest or
attenuate the progression of SBMA, several promising therapeutic
strategies developed in animal models have emerged from basic
research.
5.1. Anti-androgen therapy
The ligand-dependent nature of SBMAoffers the uniqueopportu-
nity to develop a therapy based on the reduction of androgens in the
serum. Leuprorelin is a luteinizing hormone-releasing hormone
analog that reduces testosterone levels in the serum by decreasing
release from testis. Leuprorelin showed tremendous beneﬁts in
SBMA transgenic mice, reversing symptoms and histopathological
phenotype [44]. Treatment of SBMA mice with leuprorelin de-
creased the accumulation of insoluble polyQ-AR in the nucleus in
spinal cord as well as skeletal muscle. Importantly, leuprorelin re-
duced both polyQ-AR aggregation and inclusion formation in SBMA
mice. These results were translated into a phase II clinical trial,
which proved a beneﬁcial effect of leuprorelin associated with
amelioration of swallowing together with a reduction of polyQ-AR
stabilization and nuclear accumulation [5]. More recently, a larger
randomized, placebo-controlled, multi-center clinical trial con-
ﬁrmed that leuprorelin treatment reduces accumulation of
polyQ-AR, but did not show any signiﬁcant effect on swallowing
function in patients with SBMA [48]. Leuprorelin decreased the lev-
els of creatine kinase in the serum and reduced the accumulation of
polyQ-AR in the nucleus of scrotal skin biopsies of treated patients.
Moreover, leuprorelin inhibited the nuclear accumulation of
polyQ-AR in the spinal cord and brainstem autoptic specimens of
an SBMA patient that had been under treatment for two years [5].
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press high levels of 5-alpha-reductase suggests that the conversion
of testosterone to DHT represents a potential therapeutic target for
disease. Consistent with this idea, a 2-year double-blind placebo-
controlled trial with the 5-a-reductase inhibitor dutasteride
showed an improvement, although not signiﬁcant, on muscle
strength and a beneﬁt in physical quality of life [24].
5.2. Clearance of mutant protein
Cells have evolved two mechanisms for the degradation of
misfolded proteins: the ubiquitin–proteasome system (UPS) and
lysosome-mediated autophagy. The observation that Hsp overex-
pression attenuates polyQ-AR toxicity indicates that enhancing
protein quality control systems might be a viable therapeutic strat-
egy for SBMA. Hsp synthesis can be induced by oral administration
of the acyclic isoprenoid geranylgeranylacetone (GGA). In SBMA
cells, GGA increased the levels of expression of Hsp70, Hsp90,
and Hsp105, leading to inhibition of cell death. In SBMA mice,
treatment with GGA resulted in amelioration of the neuromuscular
phenotype, which was associated with increased expression of sev-
eral Hsps via activation of heat shock factor-1 and reduction of nu-
clear accumulation of polyQ-AR [49]. Another approach to activate
the heat shock response is the use of the benzoquinone ansamycin
geldanamycin, which promotes the degradation of Hsp90 client
proteins through the UPS [93]. Unfortunately, this compound is
highly toxic and cannot be used for prolonged therapy in humans.
A less toxic derivative of geldanamyin is 17-allylamino-17-
demethoxygeldanamycin (17-AAG). PolyQ-AR has higher afﬁnity
for p23-Hsp90 complex than wild type AR. The major pharmaco-
logical effect of 17-AAG, a potent Hsp90 inhibitor, is to promote
the dissociation of p23 from the Hsp90-AR complex, leading to en-
hanced proteasomal degradation of the disease protein. Adminis-
tration of this compound markedly reduced motor neuron
degeneration and increased survival in SBMA mice through in-
creased degradation of monomeric and aggregated mutant AR
[89,114]. Interestingly, in motor neuron-derived cells 17-AAG has
been shown to protect from toxicity by promoting polyQ-AR deg-
radation through autophagy rather than proteasome [89]. Re-
cently, Sobue and colleagues described the therapeutic efﬁcacy of
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-
DMAG), a more potent and water-soluble Hsp90 inhibitor, on the
phenotype of SBMA mice [108]. In cell cultures and transgenic
mice, the protective effect of 17-DMAG was associated with en-
hanced degradation of pathogenic AR through the UPS.
PolyQ-AR is also degraded via autophagy. In cultured motor
neurons, pharmacologic induction of both mTOR-dependent and
mTOR-independent pathways of autophagy leads to the degrada-
tion of cytoplasmically retained polyQ-AR, which in turn results
in the reduction of the toxic effects of mutant protein [68]. Autoph-
agy can be induced by rapamycin, an inhibitor of the autophagy-
negative regulator TOR. Treatment with rapamycin suppressed
the neurodegeneration caused by polyQ-AR in SBMA ﬂies [81]. Re-
cent studies in models of amyotrophic lateral sclerosis and polyQ
diseases suggest that the HspB8 removes misfolded proteins by
activation of the autophagosome-lysosome pathway, highlighting
HspB8 as a novel therapeutic target for these disorders [13,14].
5.3. Modulation of N/C interaction
The new evidence showing a role of the N/C interaction in dis-
ease pathogenesis highlights this ligand-induced post-transla-
tional modiﬁcation as a novel therapeutic target for SBMA.
Flutamide is a non-steroidal anti-androgen known to reduce or
prevent the N/C interaction, and is already used for prostate cancer
treatment. In SBMA mice, ﬂutamide had no effect on disease pro-gression and manifestations [44]. However, ﬂutamide showed ben-
eﬁcial effects when administered at the prenatal stage in
transgenic mice that develop muscle atrophy due to overexpres-
sion of normal AR solely in muscle, suggesting a potential beneﬁ-
cial effect when administered in very early developmental stages
[42,67]. Another anti-androgen that reduces the AR N/C interaction
is bicalutamide, which has recently been shown to reduce polyQ-
AR aggregation and prevent DHT-dependent toxicity in PC12 cells
expressing an AR with 112 glutamine residues and in primary mo-
tor neurons obtained from SBMA mice [75]. The effect of these
anti-androgens suggests that selective AR modulators (SARMs)
with the ability to inhibit the AR N/C interaction may be effective
in SBMA. Consistent with this idea, the two SARMs RTI-016 and
RTI-051b that inhibit AR N/C interaction were shown to induce nu-
clear translocation of AR in the absence of aggregation and toxicity
[75]. Whether these SARMs will be effective in vivo is not yet
known.
5.4. Targeting nuclear inclusion formation
Another potential therapeutic target for SBMA and other polyQ
diseases is inclusion formation. The ﬁnding that inclusion forma-
tion can be associated with protection, rather than toxicity, has
provided the rationale for identiﬁcation of compounds that pro-
mote inclusion formation [4]. One such compound is B2, which
has been shown to increase inclusion formation and reduce toxic-
ity in cell models of Huntington’s disease [9]. Recently, we showed
that treatment of cell and ﬂy models of SBMA with B2 results in in-
creased accumulation of mutant AR into inclusions and reduced
toxicity, further supporting the idea that accumulation of polyQ-
expanded protein into inclusions is protective [79]. Interestingly,
we found that the effect of B2 on inclusion formation and toxicity
was associated with decreased AR transactivation, suggesting that
AR function is important for pathogenesis. Ampliﬁcation of the na-
tive function of polyQ protein has been proposed to be a critical
component of polyQ disease pathogenesis [59,72]. The protective
effect of B2 in SBMA cells may be the result of a primary effect
on the accumulation of polyQ-AR into inclusions, which as a conse-
quence may lead to reduced interaction with transcription co-reg-
ulators, reduced AR transactivation and attenuation of toxicity.
5.5. Targeting the interaction of AR with transcriptional co-regulators
The observation that the interaction of polyQ-AR with critical
co-regulators (co-repressors and co-activators of transcription) is
pathogenic highlights the relevance of this pathway as a therapeu-
tic target [72]. This concept is supported by the observation that
treatment of SBMA mice with the curcumin-related compound
5-hydroxy-1,7-bis(3,4-dimethoxyphenyl)-1,4,6-heptatrien-3-one
(ASC-J9) disrupted the interaction between AR and its co-regulator
ARA70 and improved disease symptoms by decreasing nuclear
aggregation and increasing mutant AR clearance [116]. Treatment
of the mice with ASC-J9 did not alter the levels of testosterone in
the serum of SBMA mice, thereby avoiding side effects on sexual
activity and fertility. As new curcumin analogs have been identi-
ﬁed, it would be interesting to determine whether any of them
has beneﬁcial effects in SBMA [95].
5.6. Targeting native AR function
Transcription dysregulation is a primary pathogenic process in
polyQ diseases. Altered gene expression is a consequence not only
of sequestration of transcription factors and co-regulators, but also
of altered chromatin remodeling. One of the major modiﬁcations of
chromatin involves histone acetylation, which is associated with
gene expression, and histone deacetylation, which is associated
422 S. Parodi, M. Pennuto / Frontiers in Neuroendocrinology 32 (2011) 416–425with gene silencing. Histone acetylation is dependent on two
opposing classes of proteins: the histone acetyltransferases (HATs)
and the histone deacetylases (HDACs). Disruption of the normal
balance between histone acetyltransferase and deacetylase activi-
ties has deleterious consequences on proper gene expression pat-
terns. PolyQ proteins sequester some HAT proteins, such as
CREB-binding protein (CBP) [64,105]. Overexpression of CBP res-
cued histone acetylation and neurodegeneration in ﬂy and mouse
models of polyQ diseases. These studies suggest that inhibition of
HDAC activity may be of therapeutic value. Indeed, the HDAC
inhibitor sodium butyrate has been shown to ameliorate the neu-
rological phenotype of SBMA transgenic mice, and this effect was
associated with increased acetylation of nuclear histones in neural
tissues [66].
5.7. Growth factors and neurotrophins
Altered gene expression as well as disruption of axonal trans-
port may contribute to polyQ disease pathogenesis by decreasing
trophic support for neurons. Among the genes that have been
shown to be down-regulated in mouse models of SBMA are the
vascular endothelial growth factor (VEGF), insulin-like growth fac-
tor 1 (IGF-1), glial cell line-derived neurotrophic factor (GDNF),
transforming growth factor-beta, and neurotrophin-4 [46,97,118].
Activation of VEGF and IGF-1 signaling has been shown to be ben-
eﬁcial in SBMA mouse models, indicating this as a novel therapeu-
tic strategy to attenuate disease manifestations [80,97].
Interestingly, we have previously shown that muscle-restricted
overexpression of a muscle-speciﬁc isoform of IGF-1 (mIGF-1) in
SBMAmice protects from the toxicity of polyQ-AR via a mechanism
that involves direct modiﬁcation of the disease protein [80]. mIGF-
1 activated Akt in muscle of SBMA mice, which then in turn stim-
ulated the phosphorylation of polyQ-AR and its turnover through
proteasome. Activation of the IGF-1/Akt signaling in muscle not
only resulted in a remarkable amelioration of muscle, but also of
spinal cord pathology together with amelioration of motor dys-
function and increased survival. These ﬁndings support the idea
that muscle represents a critical tissue target of polyQ-AR toxicity
and highlight that intervention in muscle may be therapeutically
relevant for SBMA.
5.8. Physical exercise
Frequent, moderate-intensity aerobic training in patients with
muscular dystrophies and metabolic myopathies has shown bene-
ﬁcial effects [30,41,73,74,100]. Most of these patients have clinical
characteristics similar to patients with SBMA, such as muscle
weakness and wasting along with a sedentary lifestyle. Moreover,
physical exercise can increase the production of IGF-1 and other
growth factors from muscle, which may have beneﬁcial effects
on muscle and spinal cord. Preisler and colleagues tested the effect
of aerobic training for three months in eight SBMA patients [86].
There was an amelioration of certain aspects of disease manifesta-
tions, but the effect of exercise was limited. It remains to be estab-
lished whether prolonged exercise training is of any therapeutic
efﬁcacy in SBMA patients.6. Concluding remarks
The discovery of polyQ expansion in the gene encoding AR as
the mutation responsible for SBMA dates to the early 1990s [55].
Two decades later, however, there is no effective therapy for SBMA
and the other neurodegenerative diseases caused by expanded
polyQ. Ligand binding to polyQ-AR converts the disease protein
into a toxic species by altering several cellular processes, includingprotein folding, transcriptional regulation and mitochondrial func-
tion. From a therapeutic point of view, each of these pathways may
represent a worthwhile avenue to pursue for development of ther-
apy for SBMA. It is possible that effective therapy will come from
combination therapy. For instance, a therapy based on the use of
anti-androgens together with agents that reduce any of the
ligand-induced modiﬁcations of mutant protein might be worth-
while to pursue.
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